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Available online 3 June 2017SET-M33 is amultimeric antimicrobial peptide active against Gram-negative bacteria in vitro and in vivo. Insights
into its killing mechanism could elucidate correlations with selectivity.
SET-M33 showed concentration-dependent bactericidal activity against colistin-susceptible and resistant isolates
of P. aeruginosa and K. pneumoniae. Scanning and transmission microscopy studies showed that SET-M33 gener-
ated cell blisters, blebs,membrane stacks and deep craters in K. pneumoniae and P. aeruginosa cells. NMR analysis
and CD spectra in the presence of sodiumdodecyl sulfatemicelles showed a transition from an unstructured state
to a stable α-helix, driving the peptide to arrange itself on the surface of micelles.
SET-M33 kills Gram-negative bacteria after an initial interaction with bacterial LPS. The molecule becomes then
embedded in the outer membrane surface, thereby impairing cell function. This activity of SET-M33, in contrast
to other similar antimicrobial peptides such as colistin, does not generate resistant mutants after 24 h of expo-
sure, non-speciﬁc interactions or toxicity against eukaryotic cell membranes, suggesting that SET-M33 is a prom-
ising new option for the treatment of Gram-negative antibiotic-resistant infections.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Extensive use of broad-spectrum antibiotics has led to the develop-
ment and spread of extensively antibiotic-resistant strains of bacteria,
making antimicrobial resistance a global problem. Antibiotic-resistant
bacteria kill 25,000 people in the EU every year. Infections such as uri-
nary tract infections [1], pneumonia [2] and septicemia [3] are increas-
ingly associated with multi-drug resistant Gram-negative bacteria in
all regions of the world [4]. These antibiotic-resistant bacteria generally
cause infections associated with increased risk of poor clinical outcome
and mortality compared to non-resistant strains of the same bacteria
[5]. TheWorld Health Organization warns that antimicrobial resistance
is an increasingly serious threat to global public health and calls forrobiology & Infectious Diseases,
erlands.
. This is an open access article underaction across all government sectors and society [6] to avoid a dreaded
“post-antibiotic” era.
A recent rekindling of antibiotic research has shown that the antimi-
crobial peptide class of antibiotics is particularly promising for use
against infections caused by multidrug-resistant microorganisms [7–
9]. Antimicrobial peptides (AMPs) are an important component of the
natural defenses of most living organisms, and N2500 AMPs have been
registered in the Antimicrobial Peptide Database (http://aps.unmc.
edu/AP/main.php) [10]. However, despite their desirable characteris-
tics, antimicrobial peptides have had limited pharmaceutical develop-
ment due to their toxicity, instability and manufacturing costs, and
therefore only a few AMPs have actually been approved for clinical
use [11–12].
Themost commonmechanism of antimicrobial killing by antimicro-
bial peptides is disruption of the cytoplasmicmembrane, for example by
pore formation, which is rather non-speciﬁc but highly efﬁcient [13–
15]. Alternative mechanisms of action include peptide translocation
into the cytoplasm where the antibiotic interferes with bacterial meta-
bolic processes, such as protein synthesis or DNA replication, whilethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1797H. van der Weide et al. / Biochimica et Biophysica Acta 1859 (2017) 1796–1804other peptides are known to interact directly with speciﬁc membrane
components [16–18]. In particular, cationic AMPs have been demon-
strated to induce anionic lipid clustering which appears to arrest bacte-
rial growth or trigger cell death [19–20].
SET-M33 is an antimicrobial peptide that has been extensively stud-
ied in recent years [21–25]. It is a cationic non-natural peptide built in a
branched form (Fig. 1) thatmakes itmore resistant to degradation in bi-
ological ﬂuids [26]. SET-M33 has shown efﬁcacy against a number of
Gram-negative multi-drug and extensively drug-resistant clinical iso-
lates [21,24]. It has also shown acceptable toxicity in human cells and
in mice [22], as well as anti-inﬂammatory activity [23]. Nevertheless,
its mechanism of action has not yet been researched in depth. In this
study we used different techniques to study the mechanism of action
of SET-M33 against two Gram-negative bacterial species, K. pneumoniae
and P. aeruginosa: 1) bacterial killing kinetics over time to see concen-
tration-dependency and onset of resistance; 2) electronmicroscopy im-
aging of treated bacteria to visualize membrane disturbance; 3)
hemolytic activity to assess eukaryotic cell toxicity and 4) NMR and cir-
cular dichroism to study the structure of the peptides in the presence of
micelles and their ability to stabilize in a facial amphiphilic helix.
2. Materials and methods
2.1. Peptide synthesis
All peptides were prepared by solid-phase synthesis through stan-
dard Fmoc chemistry using a Syro multiple peptide synthesizer
(MultiSynTech, Witten, Germany). Side chain protecting groups were
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for R, t-
butoxycarbonyl for K and t-butyl for S (Iris Biotech GmbH,
Marktredwitz, Germany). The ﬁnal products were cleaved from the
solid support, de-protected by treatment with TFA containing
triisopropylsilane and water (95/2.5/2.5), and precipitated with diethyl
ether. Final peptide purity and identitywas conﬁrmed by reverse-phase
chromatography on a Phenomenex Jupiter C18 analytical column (300
Å, 250 × 4.6 mm) and by mass spectrometry.
Q-33 (linear peptide, QKKIRVRLSA) was produced on TentaGel S
RAM resin (Iris Biotech GmbH, Marktredwitz, Germany). The crude
peptide, released as amide,was puriﬁed by reverse-phase chromatogra-
phy on a Phenomenex Jupiter C18 column (300 Å, 250 × 10 mm), in a
linear gradient, using 0.1% TFA/water as eluent A and acetonitrile as el-
uent B (from 99% to 50% of A in 30 min). The compound was character-
ized on aMALDI-TOFmass spectrometer (Ultraﬂex III Bruker Daltonics):
QKKIRVRLSA-NH2, MALDI-MS: 1198.97 [M + H]+; RP-HPLC: tR =
19.62 min, purity N 99%.
SET-M33 (tetrabranched peptide, (KKIRVRLSA)4K2KβΑ-ΟΗ) was
synthesized on a Fmoc4-Lys2-Lys-β-Ala Wang resin (Iris BiotechNH
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Fig. 1. Structure of SET-M33.GmbH,Marktredwitz, Germany). The crude peptide, released as carbox-
ylic acid, was puriﬁed by reverse-phase chromatography on a
Phenomenex Jupiter C18 analytical column (300 Å, 250 × 10 mm) in a
linear gradient, using water with 0.1% TFA as eluent A and acetonitrile
as eluent B (from 82% to 75% of A in 60 min). The puriﬁed peptide was
obtained as a triﬂuoroacetate salt and exchanged to acetate using a qua-
ternary ammonium resin (AG1-X8, 100–200 mesh, 1.2 meq/mL capac-
ity). The resin-to-peptide ratio was 2000:1, resin and peptide were
stirred for 1 h, the resin ﬁltered off, washed extensively and the peptide
recovered and freeze-dried. The compound was characterized on a
MALDI-TOF mass spectrometer (Ultraﬂex III Bruker Daltonics):
(KKIRVRLSA)4K2KβΑ-ΟΗMALDI-MS: 4682.48 [M + H]+; RP-HPLC: tR
=21.10min, purity N 99%. SET-M33 solubility, water ≥ 20mg/mL, saline
≥ 20 mg/mL, PBS ≥ 15 mg/mL.
2.2. Selection of colistin-resistant mutants of K. pneumoniae R-DYK 4861
and P. aeruginosa B-162
K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were both ex-
tensively antibiotic-resistant clinical isolates and colistin-susceptible.
Colistin-resistant mutants of both strains were obtained by step-wise
serial passages of bacterial strains [27] in BBL™ Mueller Hinton II
(MH-II) broth (Becton, Dickinson Benelux N.V., Erembodegem, Bel-
gium) containing colistin concentrations in the range 2–64mg/L (colis-
tin sulfate, Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands).
This involved sub-culturing 100 μL of overnight culture of the bacteria
(grown in MH-II broth) into MH-II broth containing 2 mg/L colistin
and incubating overnight at 35 °C. In subsequent steps 100 μL of over-
night culture was sub-cultured intoMH-II broth containing two-fold in-
creases in the concentration of colistin until the highest colistin
concentration of 64 mg/L was achieved. Finally, 100 μL volumes were
sub-cultured onto solid MH-II medium (Becton, Dickinson Benelux
N.V., Erembodegem, Belgium). Colistin-resistant colonies were then
characterized phenotypically using VITEK® 2.
2.3. Phenotypic characterization of bacterial isolates
Phenotypic characterization of K. pneumoniae B-DYK 4861 and
P. aeruginosa B-162 isolates and their colistin-resistant mutants was
performed by determining their susceptibility for a panel of 18 different
antibiotics from themain classes of antibiotics using the VITEK® 2 anti-
microbial identiﬁcation system (BioMérieux Benelux BV, Zaltbommel,
The Netherlands) and AST-N140 cards (Vitek AMS). Interpretation of
antimicrobial susceptibility was based on EUCAST 2017 guidelines
[28] (Table 1S Supplementary data).
2.4. Antimicrobial susceptibility of bacterial isolates –MIC assay
Antimicrobial susceptibility was assessed by determining the Mini-
mum Inhibitory Concentration (MIC) of SET-M33 and colistin using
the broth microdilution technique according to 2017 EUCAST guide-
lines. The MIC assay measures visible inhibition of bacterial growth
after 24 h exposure of bacteria to antibiotic in MH-II broth. The two-
fold antibiotic concentration range used for SET-M33 and colistin was
0.063–64 mg/L.
2.5. Concentration- and time-dependent bactericidal activity of SET-M33
and colistin – TKK assay
The concentration- and time-dependent killing capacity of SET-M33
was determined using time-kill kinetic (TKK) assays, as previously de-
scribed [29]. Brieﬂy, stationary-phase MH-II broth cultures of
K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were diluted in
25 mL MH-II broth until a density of approximately 7 × 105 colony
forming units (CFU/mL) was achieved. Bacterial cultures were exposed
to antimicrobial antibiotics at 2-fold increasing concentrations for 24 h
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were taken at 0, 1, 2, 4, 6 and 24 h of antibiotic exposure and centrifuged
at 12500 ×g for 5 min to pellet the cells, which were then resuspended
in sterile PBS. Agar plates were incubated for 24 h (K. pneumoniae) or
48 h (P. aeruginosa) at 37 °C in order to determine the number of CFU.
The lower limit of quantiﬁcation in this assay was 5 CFU/mL (log 0.7).
For colistin-susceptible bacterial isolates, the two-fold antibiotic con-
centration range was 0.125–64 mg/L for SET-M33 and colistin alike.
For colistin-resistant isolates, the two-fold antibiotic concentration
range was 0.125–64 mg/L for SET-M33 and 1–512 mg/L for colistin.
Flasks showing re-growth of bacteria after 24 h antibiotic exposure
were examined for changes in antibiotic susceptibility using the antibi-
otic MIC assay described above, but with an antibiotic concentration
range of 0.5–512 mg/L for the colistin-resistant isolates.
2.6. Sample preparation for electron microscopy
P. aeruginosa PAO1 and K. pneumoniae ATCC 13833 cells in logarith-
mic phase were resuspended at 2 × 108 CFU/mL in PBS and incubated
with 1.5 μM SET-M33 at room temperature for 15, 30 and 60 min. The
mixture was then centrifuged for 5 min at 10000 r.p.m.
2.7. Scanning electron microscopy
Centrifuged bacteria were resuspended in 500 μL PBS and a drop of
liquid cell suspension was placed on untreated glass coverslip for ﬁve
minutes. The coverslip was then ﬁxed for immersion in 2.5% glutaralde-
hyde solution in phosphate buffer 0.1 M pH 7.2 (PB) for 2 h at 4 °C,
washed in PB, postﬁxed in 1% OsO4 in PB for 30 min at 4 °C, dehydrated
in an ascending alcohol series, and dried in a Balzers CPD 030 CO2 criti-
cal point dryer.
The coverslip was then mounted on an aluminum stub, coated with
20 nm gold in a Balzers MED010 sputtering device, and observed in a
Philips XL20 scanning electron microscope with an electron accelerat-
ing voltage of 20 kV.
2.8. Transmission electron microscopy
Centrifuged bacteria were ﬁxed in 2.5% glutaraldehyde solution in
phosphate buffer 0.1 M pH 7.2 (PB) for 2 h at 4 °C, washed in PB, post-
ﬁxed in 1% OsO4 in PB for 30min at 4 °C, dehydrated in an ascending al-
cohol series, incubated twice in propylene oxide and ﬁnally inﬁltrated
and embedded in epon/araldite resin that was polymerized at 60 °C
for 48 h.
Ultrathin sections (60 nm thick) were cut from samples on a
Reichert-JungUltracut E ultramicrotome,mounted on 200-mesh copper
grids, stained with uranyl acetate and lead citrate and observed in a FEI
Technai G2 SPIRIT transmission electron microscope using an electron
accelerating voltage of 100 kV under standard operating conditions.
2.9. Nuclear magnetic resonance
All NMR samples were prepared by dissolving lyophilized peptides
in 500 μL H2O/D2O (95:5) to a ﬁnal concentration of 1.0 mM, with the
exception of SET-M33, which was dissolved to a ﬁnal concentration of
0.25 mM. Since the resonance of N-terminus amide would be missed
in aqueous media due to chemical exchange, the peptide sequence of
the Q-33 peptide, bearing a leading glutamine [33–34], was used in-
stead, allowing us to gain structural information on the Lys1 residue.
Samples with micelles were prepared using 100 mM fully deuterated
sodium dodecyl sulfate (SDS-d25, Cambridge Isotopes). Paramagnetic
spectra were recorded with 2.5 mM Gd(III)(DTPA-BMA). All spectra
were acquired on a Bruker DRX Avance spectrometer operating at
14.1 Tesla at a temperature of 298 K. Two-dimensional spectra were re-
corded by accumulating 32 FIDs for 512 experiments, digitalizing over
2048 points. Spectral width was set at 6000 Hz and repetition delay at3 s. Themixing time for total correlation spectroscopy (TOCSY) and nu-
clear Overhauser spectroscopy (NOESY) spectra was set at 45/75 ms
and 100/200/300 ms, respectively. All spectra were processed to a
ﬁnal size of 2048 by 1024 points. Peak assignment and integration
were carried out with Sparky software (T. D. Goddard and D. G. Kneller,
SPARKY 3, University of California, San Francisco) while calibration of
NOE peak volumes, distance calculation and restrained torsion angle
dynamics for structure calculation were performed using Dyana [30].
2.10. Circular dichroism
CD spectra were recorded at 25 °C with a Jasco 815 spectropolarim-
eter using quartz cells having a path length of 0.1-cm. SET-M33 (100
μM) or Q-33 (100 μM) were dissolved in pure water or 30 mM SDS.
The results were processed with the application Spectra Manager II™
Suite.
2.11. Hemolytic activity
The ability of SET-M33 peptide to induce hemolysis of human red
blood cells was assessed. Whole blood (EDTA) was centrifuged
(1100 ×g) for 10 min. Red blood cells diluted 1:100 in PBS were in-
cubated for 24 h at 37 °C in PBS with two-fold serial dilution of all
peptides from 4 mg/L to 1.8 g/L. The absorbance of the supernatants
was determined in a 96-well plate at 490 nm using a microplate
reader. Date for 100% hemolysis was obtained by adding 0.1% Triton
X-100 in water. The negative control was PBS. The hemolysis rate of
each peptide was calculated with the following equation: Hemolysis
(%) = (Apeptide − APBS) / (Atriton − APBS) × 100%; were A =
absorbance.
2.12. FPLC-gel ﬁltration
LPS from P. aeruginosa (ATCC 27316, Sigma Aldrich) and SET-M33
was gel-ﬁltered on a Superdex 75 10/300GL fast protein liquid chroma-
tography column using an AKTA Puriﬁer (GE Healthcare) in PBS pH 7.4.
100 μL of 2 g/L SET-M33or 13 g/L LPS or 13 g/L LPS+2 g/L SET-M33was
injected on a Superdex 75 10/300 GL column with a ﬂow rate of
0.75 mL/min and absorbance was measured at 220 and 260 nm.
3. Results and discussion
The K. pneumoniae and P. aeruginosa isolates used in the following
experiments were resistant to a wide range of beta-lactam antibiotics
(penicillins, cephalosporins and carbapenems) including the 4th gener-
ation cephalosporin cefepime, aminoglycosides (gentamycin and
tobramycin) and ﬂuoroquinolones (ciproﬂoxacin and norﬂoxacin). In-
terpretation of antimicrobial susceptibility was based on European
Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017
guidelines [28].
3.1. Susceptibility of bacterial isolates to SET-M33 and colistin – minimum
inhibitory concentration MIC
The susceptibility of the colistin-susceptible K. pneumoniae B-DYK
4861 and P. aeruginosa B-162 isolates and their colistin-resistant
mutants to SET-M33 and colistin in terms of MIC are shown in Table 1.
3.2. SET-M33 and colistin activity against colistin-susceptible and colistin-
resistant K. pneumoniae B-DYK 4861 and P. aeruginosa B-162 – time-kill-
kinetics TKK
Themajor killing effect of an antibiotic against an organism depends
on the exposure time or concentration of the drug at the active target
site. In the present study we investigated extensively drug-resistant K.
Table 1
MICs of SET-M33 and colistin for bacterial isolates in triplicate.
Bacterial isolate Colistin-susceptible
K. pneumoniae
R-DYK 4861
Colistin-resistant
K. pneumoniae
R-DYK 4861
Colistin-susceptible
P. aeruginosa
B-162
Colistin-resistant
P. aeruginosa
B-162
AMP Median Range Median Range Median Range Median Range
SET-M33 mg/L 16 16–16 16 16–32 16 8–16 16 8–16
μM 2.7 2.7–2.7 2.7 2.7–5.5 2.7 1.4–2.7 2.7 1.4–2.7
Colistin mg/L 0.50 0.25–0.50 N512 N512 2 2–2 512 128–512
μM 0.22 0.11–0.22 N222 N222 0.87 0.87–0.87 222 55–222
Colistin resistance did not affect SET-M33 susceptibility in these two strains, conﬁrming our previous data on seven different colistin-resistant K. pneumoniae strains [21].
SET-M33 showed a MIC of 8 mg/L for K. pneumoniae ATCC 13833 and P. aeruginosa PAO1 [21].
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sure time and concentration into account.
Colistin-susceptible and colistin-resistant K. pneumoniae isolates
were killed by ≥99.9% after 2 h of exposure to ≥4 mg/L and ≥8 mg/L
SET-M33, respectively (the ﬁrst concentration above the grey shade in
Fig. 2A, B). This was followed by bacterial re-growth up to the level of
non-exposed bacteria after 24 h exposure to ≤4 mg/L and ≤16 mg/L,
respectively. Colistin killed ≥99.9% of the colistin-susceptible
K. pneumoniae isolate after 2 h of exposure to ≥0.5 mg/L (Fig. 2C) and
bacterial re-growth after 24 h exposure was observed up to ≤32 mg/L.
In the colistin-resistant isolate, colistin concentration-dependent
killing was observed in the ﬁrst hour of exposure but ≥99.9% killing
was not achieved after 2 h of exposure (Fig. 2D).
For P. aeruginosa, ≥99.9% killing was achieved in colistin-susceptible
and colistin-resistant isolates after 2 h of exposure to ≥8mg/L SET-M33
(Fig. 2E and F).
Colistin killed ≥99.9% of bacteria in the colistin-susceptible P.
aeruginosa isolate after 2 h of exposure to a concentration ≥ 1 mg/L
(Fig. 2G). In the colistin-resistant P. aeruginosa isolate, colistin concen-
tration-dependent killing was observed in the ﬁrst 2 h of exposure,
followed by bacterial re-growth up to the level of non-exposed bacteria
after 24 h, at all the colistin concentrations tested (Fig. 2H).
We also showed that exposure to SET-M33 sterilized colistin-sus-
ceptible K. pneumoniae and P. aeruginosa populations already at one-
fold (16 mg/L) (Fig. 2A) and four-fold (64 mg/L) (Fig. 2E) the MICs, re-
spectively. In contrast, after exposure to colistin, sterilization only oc-
curred at the extremely high concentration of 64 mg/L (Fig. 2C and G),
which is 128-fold and 32-fold the MICs of colistin-susceptible K.
pneumoniae and P. aeruginosa, respectively. Colistin-resistant K.
pneumoniae and P. aeruginosa were sterilized with 64 mg/L SET-M33
(Fig. 2B and F) in both cases (four-fold the MIC) but never with colistin
(Fig. 2D and H).
SET-M33 and colistin showed concentration-dependent bactericidal
activity against colistin-susceptible and colistin-resistant isolates of
K. pneumoniae and P. aeruginosa. This result is similar to the action of
different widely used antibiotics e.g. aminoglycosides and ﬂuoro-
quinolones, as well as other AMPs [31].
SET-M33 retains activity against both colistin-susceptible and colis-
tin-resistant bacteria. This result indicates that SET-M33 is impervious
to the mechanisms associated with colistin resistance.3.3. Selection of resistance
Selection of resistancewas assessed in the same experiments: when
re-growth was observed after 24 h of exposure to antibiotic, bacterial
susceptibilitieswere determined asMIC. Re-growth of colistin-suscepti-
ble strains of K. pneumoniae and P. aeruginosa after 24 h of exposure to
SET-M33 was never associated with selection of SET-M33 resistance
(Table 2): in fact, MIC values did not increase more than 0.5–2 fold,
whereas re-growth of K. pneumoniae after 24 h of colistin exposure
was associated with decreased susceptibility and a manifold increase
in MIC (Table 2). Colistin was more effective against P. aeruginosa,although bacteria regrowing at 1 mg/L colistin showed a ~ six-fold in-
crease in MIC.
Similar results were obtained with the colistin-resistant strains, al-
though re-growth of colistin-resistant K. pneumoniae showed slightly
lower susceptibility to SET-M33 with a four-fold increase in MIC
(Table 2S Supplementary data).
Gram-negative bacteria can reduce their susceptibility to AMPs by
reducing their net negative surface charges, modifying capsule polysac-
charides, or reducing outer membrane ﬂuidity [32]. In contrast to colis-
tin, resistance to SET-M33 does not readily develop during 24 h of
continuous exposure. This ﬁnding provides evidence that some of the
resistance mechanisms that affect colistin do not affect SET-M33 to
the same extent. For example, the mutations that lead to colistin resis-
tancemay not have the same effect on the activity of SET-M33, or alter-
natively, exposure to SET-M33 may not elicit the type of resistance
mutations that are selected or induced by colistin. Ways of avoiding re-
sistancewill be investigated in further studies. Importantly, the fact that
resistance to SET-M33 does not appearwithin 24 exposure period to the
antibiotic provides evidence that the use of SET-M33 in the clinic may
have advantages over the use of colistin. For example, colistin is current-
ly used as an antibiotic of last resort for MDR bacteria [33–34], but be-
sides its toxic side effects, it is also becoming dangerously more often
ineffective due to increasing number of resistant strains [35–37].
3.4. Electron microscopy
The effect of SET-M33 treatment at MIC (8mg/L SET-M33) for 15, 30
and 60 min on bacterial cell morphology was studied by scanning elec-
tron microscopy (SEM) and transmission electron microscopy (TEM).
SEM images showed that after 30 min of SET-M33 treatment, the sur-
faces of K. pneumoniae ATCC 13833 and P. aeruginosa PAO1 cells lost
their smoothness and developed superﬁcial blisters (Fig. 3). After
60 min of SET-M33 treatment, bacterial cells appeared larger than con-
trol cells and many were empty and showed large holes, mainly at the
poles.
TEM microscopy (Fig. 4) showed signiﬁcant signs of alteration in
most bacterial cells after 30 min of SET-M33 treatment: P. aeruginosa
and K. pneumoniae cells appeared turgid and ﬁlamentous material ap-
pears on the external side of the outer membrane.
In the ﬁrst 30 min after incubation with SET-M33, only a few K.
pneumoniae and P. aeruginosa bacterial cells (rare in the micrograph
ﬁeld) showed cell damage.
Some linear peptides are reported to kill bacteria very quickly [16],
while others, such as magainin-2, kill bacteria after 15–90 min. SET-
M33 damages bacteria in the latter time range: indeed microscopy
only showed initial signs of bacterial membrane disturbance in very
few cells after 10–15 min of exposure. With longer exposure, the dam-
age to bacterial membranes increased in frequency and severity.
3.5. Peptide conformation – NMR structure analysis and circular dichroism
The supramolecular structure of peptides is important and has been
extensively studied in interactions of peptides with bacterial
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Fig. 2. Concentration- and time-dependent bactericidal activity of SET-M33 and colistin against isolates of K. pneumoniae R-DYK 4861 (A-D) and P. aeruginosa B-162 (E-H). Bacterial
cultures were exposed to two-fold increasing concentrations of SET-M33 or colistin for 24 h at 37 °C under shaking conditions. Samples were collected at 1, 2, 4, 6 and 24 h, and after
centrifuging and washing, were sub-cultured onto antibiotic-free solid media to determine CFU counts after incubation for 24 h at 37 °C. Data are medians of 3 experiments. Grey
shading indicates ≥99.9% killing achieved after 2 h of exposure.
1800 H. van der Weide et al. / Biochimica et Biophysica Acta 1859 (2017) 1796–1804membranes [16,38–39]. The NMR spectra of free SET-M33 showed a
chemical shift index typical of a randomcoiled conformation andno sig-
niﬁcant inter-residue NOEs, indicating that the peptide explores a large
conformational space. On addition of sodium dodecyl sulfate (SDS) mi-
celles, theNMR spectrumof SET-M33undergoes a generalized broaden-
ing, caused by the production of slow-tumbling high-mass species,
precluding further analysis. The high-mass species could be aggregates
of SET-M33-SDS, possibly promoted by the multimericity of SET-M33.
We therefore synthesized an analogue peptide, Q-33, in linear form
and capped it with an additional amino acid (Q-KKIRVRLSA) at the N-
terminus in order to generate amodel of SET-M33 that could be studiedin the presence of SDS. Q-33 has an extremely lower half life in serum
and plasma than SET-M33, 2 h versus 24 h, and consistently it has a
lower activity against Gram-negative bacteria [40–41]. The additional
Q allowed us to study the structure of all residues, including the ﬁrst ly-
sine. Q-33 did not show any stable conformation in water, but addition
of SDS micelles caused a generalized dispersion of proton resonances
and the emergence of NOE peaks, indicating that a stable conformer
was present as a consequence of the peptide-micelle interaction. In par-
ticular, NOE signals of the Hαi-HNi+3, Hαi-Hβi+3 andHNi-HNi+2 types
for residue i= 1 to 6 are diagnostic of α-helix conformation spanning
residues 1–9 (Fig. 5A). Peak integration of a total set of 32 NOEs allowed
Table 2
Change in colistin-susceptible K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 susceptibility to SET-M33 and colistin after 24 h exposure to antibiotic as determined by MIC assay.
Antibiotic concentration (mg/L) SET-M33 (mg/L) Colistin (mg/L)
Colistin-susceptible K. pneumoniae Colistin-susceptible P. aeruginosa Colistin-susceptible K. pneumoniae Colistin-susceptible P. aeruginosa
Control 16 16 0.5 2
0.125 16 16 N64 2
0.25 16 16 N64 2
0.5 16 16 N64 4
1 16 16 N64 12a
2 16 16 N64 NR
4 32 16 N64 NR
8 NR 16 64a NR
16 NR 12a N64b NR
32 NR NR N64a NR
64 NR NR NR NR
Colistin-susceptible bacterial cultures were exposed to two-fold increasing concentrations of SET-M33 or colistin for 24 h at 37 °C under shaking conditions. When bacteria re-grew after
24 h exposure to antibiotic, their MIC susceptibilities (performed in triplicate) were also determined and the median value reported. NR, no bacterial re-growth.
a One out of three samples did not show bacterial re-growth.
b Two out of three samples did not show bacterial re-growth.
1801H. van der Weide et al. / Biochimica et Biophysica Acta 1859 (2017) 1796–1804us to calculate the relative interproton distances, which were used as
constraints for simulation of torsion angle dynamics and subsequent
peptide structure calculations. The resulting structure showed a regular
α-helix encompassing the full-length of the peptide.
To assess the interaction geometry of the helix with SDS micelles, a
paramagnetic solution-NMR experiment was performed. TOCSY (total
correlation spectroscopy) spectra of the peptide-micelle system were
acquired in the presence and absence of increasing concentrations of
the paramagnetic probe Gd(III)(DTPA-BMA). The soluble probe causes
nuclear spin relaxation proportional to the local surface accessibility of
the molecule investigated [42–44]. Relaxation is measured by calculat-
ing the decrease in peak volumes on addition of the probe, and is sum-
marized as a bare number, the attenuation value A, which ranges from 0
to 2 and can be determined for each known proton peak. Protons
shielded by contact with the solvent, and therefore not accessible to
the probe, show low A values, while exposed protons show high A
values (Fig. 5B, upper part). Attenuation analysis was carried out on
the Q-33-micelle systemand an accurate accessibility proﬁle was deter-
mined. Residues I3 and L7 showedmuch lower accessibility of the probe
to their sidechains, and this can be ascribed to shielding by closeFig. 3. Scanning electron micrographs (SEM) of K. pneumoniae ATCC 13833 and P. aeruginosa
incubation with SET-M33 at MIC; C) K. pneumoniae after 60 min incubation with SET-M33 at M
MIC; F) P. aeruginosa after 60 min incubation with SET-M33 at MIC. Scale bar 2 μm.interaction with the micelle surface. Charged residue pairs K1/R4 and
K2/R6, situated on the opposite side of the helix, showed a higher A
value, while V5 and S8 showed the highest attenuation due to their
high exposure to the solvent. The resulting structure was a helix lying
on the micelle surface with I3/L7 sidechains inserted into the SDS as-
sembly, and R and K sidechains arranged parallel to the surface, their
charged tips interacting with the negative sulfate groups (Fig. 5B).
This facial amphiphilic structure has already been reported for other
positively charged peptides [45], such as LL37 fragments [46] and
CRAMP [47].
Finally, we wanted to assess whether SET-M33 and Q-33 had the
same ability to adopt a helix conformation in a membrane mimicking
environment, using circular dichroism. The technique proved to be ap-
plicable to both the tetrabranched and the linear peptide. SET-M33
and Q-33 CD spectra were recorded at room temperature in water and
in SDS 30 mM. In line with the NMR experiments, SET-M33 showed a
non-structured conformation in water but the CD spectrum shifted
sharply to longer wavelengths in the presence of SDS micelles (Fig.
5C), and the calculated helix ratio switched from 0% to 30%. A similar re-
sult was obtained with Q-33 (Fig. 5D): the spectra recorded in waterPAO1. SEM micrographs of A) untreated K. pneumoniae; B) K. pneumoniae after 30 min
IC; D) untreated P. aeruginosa; E) P. aeruginosa after 30 min incubation with SET-M33 at
Fig. 4. Transmission electron micrographs (TEM) of K. pneumoniae ATCC 13833 and P.
aeruginosa PAO1. TEM micrographs of A) untreated K. pneumoniae; B) K. pneumoniae
after 60 min incubation with SET-M33 at MIC; C) untreated P. aeruginosa; D) P.
aeruginosa after 60 min incubation with SET-M33 at MIC. Scale bar 500 nm.
1802 H. van der Weide et al. / Biochimica et Biophysica Acta 1859 (2017) 1796–1804had a calculated helix ratio of 3.3% compared to 39% in the presence of
SDS micelles. The CD spectra of SET-M33 and Q-33, recorded with or
withoutmicelles, were very similar, conﬁrming that Q-33was a reliable
model of SET-M33 for the NMR experiments.Fig. 5. A) NOESY spectrum of Q-33 peptide in the presence of SDS micelles showing the Hα-H
interaction geometry with micelle surface (dashed line) as derived from NMR data, attenuatio
peptide/SDS sample are reported in the upper part. C) CD spectrum of SET-M33100 μM in wat3.6. Selectivity/hemolytic activity
The ability of cationic peptides to stabilize as an α-helix, and partic-
ularly as a facial amphiphilic structure, is often associated with self-ag-
gregation and undesired peptide interactionswith blood proteins due to
exposed hydrophobic surfaces [45]. The tendency to self-aggregate is
correlated to hydrophobicity and provides an indirect estimate of the
propensity for partitioning into lipid membranes with unselective de-
tergent-like characteristics. Antimicrobial peptides need to be selective
for prokaryotic membranes; a well-established method of verifying
their ability to damage eukaryotic cell membranes is to measure their
hemolytic activity [48]. Our results showed that red blood cells incubat-
ed with increasing concentrations of SET-M33 did not showmore than
26% lysis, even using a concentration of 1.8 mg/mL (320 μM),which is N
100-fold the MIC (Fig. 6).
In contrast with other cationic peptides [49], SET-M33 showed very
little hemolytic activity against red blood cells, although it shares the
ability to form a regular α-helix shape. Indeed, SET-M33 also proved
not to be cytotoxic to human bronchial epithelial cells (16HBE14 and
CFBE41) [23]. Self-aggregation, often associatedwith amphiphilic struc-
tures and undesired secondary effects [49], was also studied in FPLC ex-
periments (Supplementary material – Fig. 1S, A) and showed that no
self-aggregation occurred when SET-M33 was dissolved in PBS. The
presence of LPS promoted the formation of high-mass hetero-
multimers, but not homo-multimers (Supplementary material – Fig.
1S, B), in line with what we observed and described above in relation
to SDS.
4. Conclusions
Current understanding of the mechanism of action of cationic AMPs
includes a ﬁrst step of electrostatic attraction between the cationic pep-
tide and the negatively charged bacterial outer membrane. As SET-M33
is a cationic amphiphilic peptide it is attracted to the negatively charged
bacterial membrane. Once close to the microbial surface, AMPs need to
cross the polysaccharide cell wall barrier before interacting with theN correlation path typical of α-helices. B) Structural model of peptide conformation and
n values A obtained by adding the soluble paramagnetic probe Gd(III)(DTPA-BMA) to the
er and SDS 30 mM. D) CD spectrum of Q-33100 μM in water and SDS 30 mM.
Fig. 6. Hemolytic activity of SET-M33. Percentage of red blood cell hemolysis after 24 h
incubation at 37 °C. The range of MIC90 for K. pneumoniae and P. aeruginosa is indicated.
1803H. van der Weide et al. / Biochimica et Biophysica Acta 1859 (2017) 1796–1804cytoplasmicmembrane [15,50–51]. In linewith this, in previous studies,
SET-M33 was shown, by surface plasmon resonance, to bind LPS of K.
pneumoniae and P. aeruginosa [52] and the binding prevented TNF-α re-
lease, neutralizing endotoxin activity in vitro and in vivo [22,41]. In the
present study, NMR investigation of Q-33/SDS micelles in solution and
in the presence of a paramagnetic probe showed that the α-helix ar-
ranges itself on the surface of micelles as previously described for
other antimicrobial peptides [53–55]. Though direct measurement of
the geometry of SET-M33/SDS micelle interactions was not possible,
we demonstrated with CD that the structural transition observed
using Q-33/SDS micelles also occurs using the original tetra-branched
SET-M33 peptide. The α-helix showed to be partially buried in the
lipid-bilayer. In the course of 15–60 min, the signs of membrane dam-
ages are, indeed, evident in electron microscopy. We also knew that
SET-M33 is internalized in E. coli within 5 min, proving that it can
cross cell wall and plasma membranes [41], causing enhanced mem-
brane permeability, as observed with ﬂuorescent probes [41]. Bacteria
death may realistically be caused by impairment of the membrane ho-
meostasis and functionality.
Interestingly, SET-M33 is different from other α-helix antimicrobial
peptides in that it shows little propensity to self-aggregate and also no
hemolytic activity. Homo-aggregation, which is considered related
with undesired toxicity [48–49], is never observed. This aspect probably
contributes in preventing non-speciﬁc interactionswith eukaryotic cells
[48–49] and indeed correlates with an acceptable tolerability proﬁle ob-
tained in toxicology studies in mice [21].
SET-M33 does not show any cross-resistance with colistin in co-
listin-resistant bacteria and, differently from colistin, it appears to
generate substantially no resistance within 24 h of exposure in ex-
tensively resistant isolates of K. pneumoniae and P. aeruginosa.
These observations suggest that the two peptides have a different
mechanism of action. SET-M33 is attracted onto the surface of bacte-
ria by the anionic charges of the cell wall. Being the core of the
branched peptide completely ﬂexible, we speculate that in the pres-
ence of phospholipid-bilayers, the peptide can assume a star like
conformation, where hydrophobic residues are buried in the surface
and hydrophilic residues point outwards. The disturbance of bi-
layers integrity, produced by SET-M33's peculiar way to interact
with membranes, makes it more difﬁcult for bacteria to trigger resis-
tance mechanisms than it is for colistin.
Finally SET-M33, in contrast to other similar antimicrobial pep-
tides such as colistin, does not generate resistant mutants after
24 h of exposure, and non-speciﬁc interactions or toxicity against eu-
karyotic cell membranes, suggesting that SET-M33 is a promising
new option for the treatment of Gram-negative antibiotic-resistant
infections.Funding
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